Abstract:Recently, 'tangible' virtual libraries have made billions of molecules readily available. Prioritizing these molecules for synthesis and testing demands computational approaches, such as docking. We will present recent results in which protein structure is interrogated using molecular docking, resulting in new high-affinity compounds that exhibit new biology in animal models. Singh I, Seth A, Billesbølle CB, Braz J, Rodriguiz RM, Roy K, Bekele B, Craik V, Huang XP, Boytsov D, Pogorelov VM, Lak P, O'Donnell H, Sandtner W, Irwin JJ, Roth BL, Basbaum AI, Wetsel WC, Manglik A, Shoichet BK, Rudnick G. Structure-based discovery of conformationally selective inhibitors of the serotonin transporter. Cell. 2023 May 11;186(10):2160-2175.e17. doi: 10.1016/j.cell.2023.04.010. Epub 2023 May 2. PMID: 37137306; PMCID: PMC10306110. Fink EA, Xu J, Hübner H, Braz JM, Seemann P, Avet C, Craik V, Weikert D, Schmidt MF, Webb CM, Tolmachova NA, Moroz YS, Huang XP, Kalyanaraman C, Gahbauer S, Chen G, Liu Z, Jacobson MP, Irwin JJ, Bouvier M, Du Y, Shoichet BK, Basbaum AI, Gmeiner P. Structure-based discovery of nonopioid analgesics acting through the α2A-adrenergic receptor. Science. 2022 Sep 30;377(6614):eabn7065. doi: 10.1126/science.abn7065. Epub 2022 Sep 30. PMID: 36173843; PMCID: PMC10360211. Kaplan AL, Confair DN, Kim K, Barros-Álvarez X, Rodriguiz RM, Yang Y, Kweon OS, Che T, McCorvy JD, Kamber DN, Phelan JP, Martins LC, Pogorelov VM, DiBerto JF, Slocum ST, Huang XP, Kumar JM, Robertson MJ, Panova O, Seven AB, Wetsel AQ, Wetsel WC, Irwin JJ, Skiniotis G, Shoichet BK, Roth BL, Ellman JA. Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity. Nature. 2022 Oct;610(7932):582-591. doi: 10.1038/s41586-022-05258-z. Epub 2022 Sep 28. PMID: 36171289; PMCID: PMC9996387. Citation Format: J. Irwin. Virtual screening of ultra-large chemical spaces for novel chemotype discovery [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl) nr Wrk2-04.

Fragment-to-Lead Medicinal Chemistry Publications in 2022

Fragment-to-Lead Medicinal Chemistry Publications in 2020

Fragment-based Drug Discovery and Molecular Docking in Drug Design.

Streamlining Computational Fragment-Based Drug Discovery Through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening

Fragment Databases from Screened Ligands for Drug Discovery (FDSL-DD).

In silico Strategies to Support Fragment-to-Lead Optimization in Drug Discovery

Fragment optimization and elaboration strategies - the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hits

Overview of Recent Strategic Advances in Medicinal Chemistry

Using Fragment-Based Approaches to Discover New Antibiotics

Design and Crystallographic Screening of a Highly Sociable and Diverse Fragment Library Towards Novel Antituberculotic Drugs

Alchemical Transformations and Beyond: Recent Advances and Real-World Applications of Free Energy Calculations in Drug Discovery

FEP Augmentation as a Means to Solve Data Paucity Problems for Machine Learning in Chemical Biology

Fragment-based screening of enzyme drug targets : Microfluidic mobility shift assay improves confidence in candidate selection

Fragmenstein: predicting protein-ligand structures of compounds derived from known crystallographic fragment hits using a strict conserved-binding–based methodology

How to Find a Fragment: Methods for Screening and Validation in Fragment‐Based Drug Dscovery

Lead/Drug Discovery from Natural Resources

Linkers in fragment-based drug design: an overview of the literature

An Innovation 10 Years in the Making: The Stories in the Pages of ACS Medicinal Chemistry Letters

Abstract Wrk2-04: Virtual screening of ultra-large chemical spaces for novel chemotype discovery

Fragment-based target screening as an empirical approach to prioritising targets: a case study on antibacterials